Effects of atorvastatin and apoA-I/phosphatidylcholine discs on triglyceride-rich lipoprotein subfractions as characterized by capillary isotachophoresis

Clinica Chimica Acta

Volumn 373, Issue 1-2, 2006, Pages 55-61

  Zhang, Bo ^a   Katafuchi, Ritsuko ^b   Arishima, Hiroaki ^a   Matsunaga, Akira ^a   Rye, Kerry Anne ^c,d,e   Saku, Keijiro ^a  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HARASANSHIN HOSPITAL   (Japan)

^c HEART RESEARCH INSTITUTE   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Apolipoprotein A I phosphatidylcholine (POPC) discs; Atorvastatin; Capillary isotachophoresis (cITP); Charge based lipoprotein subfractions; Triglyceride rich lipoprotein (TRL)

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN E2; ATORVASTATIN; DYE; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PHOSPHATIDYLCHOLINE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD ANALYSIS; CAPILLARY ISOTACHOPHORESIS; CASE REPORT; DRUG EFFECT; HUMAN; HYPERLIPOPROTEINEMIA TYPE 3; IN VITRO STUDY; INFORMED CONSENT; ISOTACHOPHORESIS; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; APOLIPOPROTEIN A-I; APOLIPOPROTEIN E2; ELECTROPHORESIS, CAPILLARY; HEPTANOIC ACIDS; HUMANS; HYPERLIPOPROTEINEMIA TYPE III; LIPOPROTEINS; MACROMOLECULAR SUBSTANCES; MALE; PHENOTYPE; PHOSPHATIDYLCHOLINES; PYRROLES; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TRIGLYCERIDES;

EID: 33747877000     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2006.04.026     Document Type: Article

References (37)

1. Davignon J., and Cohn J.S. Triglycerides: a risk factor for coronary heart disease. Atherosclerosis 124 (1996) S57-S64 [Suppl.]
2. Ishigami M., Yamashita S., Sakai N., Hirano K., Hiraoka H., Nakamura T., et al. Atorvastatin markedly improves type III hyperlipoproteinemia in association with reduction of both exogenous and endogenous apolipoprotein B-containing lipoproteins. Atherosclerosis 168 (2003) 359-366
3. Cohn J.S., Marcoux C., and Davignon J. Detection, quantification, and characterization of potentially atherogenic triglyceride-rich remnant lipoproteins. Arterioscler Thromb Vasc Biol 19 (1999) 2474-2486
4. Leary E.T., Wang T., Baker D.J., Cilla D.D., Zhong J., Warnick G.R., et al. Evaluation of an immunoseparation method for quantitative measurement of remnant-like particle-cholesterol in serum and plasma. Clin Chem 44 (1998) 2490-2498
5. Okazaki M., Usui S., Tada N., Nakano T., and Nakajima K. Relation between RLP-triglyceride to RLP-cholesterol ratio and particle size distribution in RLP-cholesterol profiles by HPLC. Clin Chim Acta 296 (2000) 135-149
6. De Gennes J.L., Dairou F., Hamon P., and Truffert J. Ultracentrifugal evidence of a special subtype of mixed hyperlipidemia. Atherosclerosis 27 (1977) 493-497
7. Böttcher A., Schlosser J., Kronenberg F., Dieplinger H., Knipping G., Lackner K.J., et al. Preparative free-solution isotachophoresis for separation of human plasma lipoproteins: apolipoprotein and lipid composition of HDL subfractions. J Lipid Res 41 (2000) 905-915
8. Schmitz G., Mollers C., and Richter V. Analytical capillary isotachophoresis of human serum lipoproteins. Electrophoresis 18 (1997) 1807-1813
9. Zhang B., Noda K., and Saku K. Effect of atorvastatin on total lipid profiles assessed by analytical capillary isotachophoresis. Cardiology 99 (2003) 211-213
10. Zhang B., Matsunaga A., Saku K., Nakano S., and Yamada T. Associations among plasma lipoprotein subfractions as characterized by analytical capillary isotachophoresis, apolipoprotein E phenotype, Alzheimer disease, and mild cognitive impairment. Arterioscler Thromb Vasc Biol 24 (2004) e144-e146
11. Zhang B., Fan P., Shimoji E., Xu H., Takeuchi K., Bian C., et al. Inhibition of cholesteryl ester transfer protein activity by JTT-705 increases apolipoprotein E-containing high-density lipoprotein and favorably affects the function and enzyme composition of high-density lipoprotein in rabbits. Arterioscler Thromb Vasc Biol 24 (2004) 1910-1915
12. Zhang B., Tomura H., Kuwabara A., Kimura T., Miura S., Noda K., et al. Correlation of high density lipoprotein (HDL)-associated sphingosine 1-phosphate with serum levels of HDL-cholesterol and apolipoproteins. Atherosclerosis 178 (2005) 199-205
13. Heinen R.J., Herbert P.N., and Fredrickson D.S. Properties of the plasma very low and low density lipoproteins in Tangier disease. J Clin Invest 61 (1978) 120-132
14. Schaefer E.J., Zech L.A., Schwartz D.E., and Brewer Jr. HB. Coronary heart disease prevalence and other clinical features in familial high-density lipoprotein deficiency (Tangier disease). Ann Intern Med 93 (1980) 261-266
15. Chroni A., Kan H.Y., Kypreos K.E., Gorshkova I.N., Shkodrani A., and Zannis V.I. Substitutions of glutamate 110 and 111 in the middle helix 4 of human apolipoprotein A-I (apoA-I) by alanine affect the structure and in vitro functions of apoA-I and induce severe hypertriglyceridemia in apoA-I-deficient mice. Biochemistry 43 (2004) 10442-10457
16. Newton R.S., and Krause B.R. HDL therapy for the acute treatment of atherosclerosis. Atheroscler Suppl 3 (2002) 31-38
17. Nanjee M.N., Doran J.E., Lerch P.G., and Miller NE. Acute effects of intravenous infusion of ApoA1/phosphatidylcholine discs on plasma lipoproteins in humans. Arterioscler Thromb Vasc Biol 19 (1999) 979-989
18. Zhang B., Kaneshi T., Ohta T., and Saku K. Relation between insulin resistance and fast-migrating low density lipoprotein subfraction as characterized by capillary isotachophoresis in non-diabetic children. J Lipid Res 46 (2005) 2265-2277
19. Matz C.E., and Jonas A. Micellar complexes of human apolipoprotein A-I with phosphatidylcholines and cholesterol prepared from cholate-lipid dispersions. J Biol Chem 257 (1982) 4535-4540
20. Rye K.A., Hime N.J., and Barter P.J. Evidence that cholesteryl ester transfer protein-mediated reductions in reconstituted high density lipoprotein size involve particle fusion. J Biol Chem 272 (1997) 3953-3960
21. Mahley R.W., Huang Y., and Rall Jr. S.C. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes. J Lipid Res 40 (1999) 1933-1949
22. Bilz S., Wagner S., Schmitz M., Bedynek A., Keller U., and Demant T. Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia. J Lipid Res 45 (2004) 174-185
23. Chan D.C., Watts G.F., Barrett P.H., Mori T.A., Beilin L.J., and Redgrave T.G. Mechanism of action of a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor on apolipoprotein B-100 kinetics in visceral obesity. J Clin Endocrinol Metab 87 (2002) 2283-2289
24. Cohn J.S., Tremblay M., Batal R., Jacques H., Veilleux L., Rodriguez C., et al. Effect of atorvastatin on plasma apoE metabolism in patients with combined hyperlipidemia. J Lipid Res 43 (2002) 1464-1471
25. Forster L.F., Stewart G., Bedford D., Stewart J.P., Rogers E., Shepherd J., et al. Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates. Atherosclerosis 164 (2002) 129-145
26. Gianturco S.H., Brown F.B., Gotto Jr. A.M., and Bradley W.A. Receptor-mediated uptake of hypertriglyceridemic very low density lipoproteins by normal human fibroblasts. J Lipid Res 23 (1982) 984-993
27. Gianturco S.H., Gotto Jr. A.M., Hwang S.L., Karlin J.B., Lin A.H., Prasad S.C., et al. Apolipoprotein E mediates uptake of Sf 100-400 hypertriglyceridemic very low density lipoproteins by the low density lipoprotein receptor pathway in normal human fibroblasts. J Biol Chem 258 (1983) 4526-4533
28. Burnett J.R., Wilcox L.J., Telford D.E., Kleinstiver S.J., Barrett P.H., Newton R.S., et al. Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs. Arterioscler Thromb Vasc Biol 17 (1997) 2589-2600
29. Mangaloglu L., Cheung R.C., Van Iderstine S.C., Taghibiglou C., Pontrelli L., and Adeli K. Treatment with atorvastatin ameliorates hepatic very-low-density lipoprotein overproduction in an animal model of insulin resistance, the fructose-fed Syrian golden hamster: evidence that reduced hypertriglyceridemia is accompanied by improved hepatic insulin sensitivity. Metabolism 51 (2002) 409-418
30. Ouguerram K., Magot T., Zair Y., Marchini J.S., Charbonnel B., Laouenan H., et al. Effect of atorvastatin on apolipoprotein B100 containing lipoprotein metabolism in type-2 diabetes. J Pharmacol Exp Ther 306 (2003) 332-337
31. Verseyden C., Meijssen S., van Dijk H., Jansen H., and Castro Cabezas M. Effects of atorvastatin on fasting and postprandial complement component 3 response in familial combined hyperlipidemia. J Lipid Res 44 (2003) 2100-2108
32. Watts G.F., Barrett P.H., Ji J., Serone A.P., Chan D.C., Croft K.D., et al. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Diabetes 52 (2003) 803-811
33. Sanchez-Quesada J.L., Benitez S., Otal C., Franco M., Blanco-Vaca F., and Ordonez-Llanos J. Density distribution of electronegative LDL in normolipemic and hyperlipidemic subjects. J Lipid Res 43 (2002) 699-705
34. Ziouzenkova O., Asatryan L., Akmal M., Tetta C., Wratten M.L., Loseto-Wich G., et al. Oxidative cross-linking of ApoB100 and hemoglobin results in low density lipoprotein modification in blood. Relevance to atherogenesis caused by hemodialysis. J Biol Chem 274 (1999) 18916-18924
35. Ziouzenkova O., and Sevanian A. Oxidative modification of low-density lipoprotein (LDL) in HD patients: role in electronegative LDL formation. Blood Purif 18 (2000) 169-176
36. Sanchez-Quesada J.L., Camacho M., Anton R., Benitez S., Vila L., and Ordonez-Llanos J. Electronegative LDL of FH subjects: chemical characterization and induction of chemokine release from human endothelial cells. Atherosclerosis 166 (2003) 261-270
37. Rye K.A., and Barter PJ. The influence of apolipoproteins on the structure and function of spheroidal, reconstituted high density lipoproteins. J Biol Chem 269 (1994) 10298-10303